Medical Use of Cannabis in 2019 Kevin P. Hill, MD, MHS JAMA, Published online August 9, 2019 doi:10.1001/jama.2019.11868 Nearly 10% of cannabis users in the United States report using it for medicinal purposes.1 As of August 2019, 33 states and the District of Columbia have initiated policies allowing the use of cannabis or cannabinoids for the management of specific medical conditions. Yet, the federal government still classifies cannabis as illegal, complicating its medical use and research into its effectiveness as a treatment for the various conditions purported to benefit from cannabis pharmacotherapy. Because of this conflict and restrictions on cannabis research, evidence of the [...]
Lire la suiteOpioïdes : le cannabidiol pour réduire la dépendance ? Le cannabidiol (CBD) réduit le craving et l'anxiété chez les personnes ayant des antécédents d'abus d'héroïne/opioïdes, suggérant un rôle possible du cannabis ou de son agent le cannabidiol dans la réduction de la dépendance aux opioïdes. C’est la conclusion de cette étude réalisée à l’Icahn School of Medicine du Mont Sinaï (New York), présentée dans l'American Journal of Psychiatry. L'étude confirme également les effets anti-stress du CBD avec une baisse de la fréquence cardiaque et du taux de cortisol induites par les stimuli de drogues. La grande disponibilité des opioïdes sur prescription ces [...]
Lire la suiteThe antiaddictive effects of ibogaine : A systematic literature review of human studies Rafael G. DOS SANTOS, José Carlos BOUSO and Jaime E. C. HALLAK Journal of Psychedelic Studies, 2017, 1, (1), pp. 20–28 DOI: 10.1556/2054.01.2016.001 Background and aims : Ibogaine is a naturally occurring hallucinogenic alkaloid with a therapeutic potential for reducing drug craving and withdrawal. To the best of our knowledge, no systematic review was previously performed assessing these effects. Thus, we conducted a systematic literature review of human studies assessing the antiaddictive effects of ibogaine. Methods : Papers published up to July 2, 2016 were included from PubMed, LILACS, and SciELO databases [...]
Lire la suiteThe Treatment of Cannabis Use Disorder Itai Danovitch, David A. Gorelick, Chapter,The Assessment and Treatment of Addiction, january 2019 Abstract: Worldwide, cannabis is the most commonly used illicit substance. Approximately 8-12% of persons who use cannabis will develop cannabis use disorder (CUD) at some point in their life. Several psychosocial treatment methods have shown efficacy in controlled clinical trials, including motivational enhancement therapy, cognitive behavioral therapy, and contingency management. While no pharmacotherapy has been established as broadly effective for CUD, gabapentin and N-acetylcysteine have shown efficacy in single controlled clinical trials, and a number of promising approaches are under study. This article reviews established [...]
Lire la suiteClinical Manifestations of Cannabis Use Disorder Alan J. Budney, Jacob T. Borodovsky, and Ashley A. Knapp C Springer Nature Switzerland AG 2019 Introduction : Cannabis use disorder (CUD) or its colloquial synonym, cannabis addiction, remains controversial in that many in the general public believe that cannabis use does not pose substantial risk for harm and is not addictive in the same sense that tobacco, alcohol, cocaine, or heroin is addictive. Although assessment of people’s beliefs about addiction and harm is complicated by the lack of a consensus definition or a common understanding of addiction, the difference in perception of risk between cannabis and other [...]
Lire la suitehttps://www.canada.ca/fr/sante-canada/services/drogues-medicaments/cannabis/renseignements-medecins/renseignements-destines-professionnels-sante-cannabis-cannabinoides.html Renseignements destinés aux professionnels de la santé : Le cannabis (marijuana, marihuana) et les cannabinoïdes (Version PDF - 2,690 Ko) Plante séchée ou fraîche et huile destinées à l'administration par ingestion ou par d'autres moyens Agent psychoactif Le présent document a été préparé par la Direction générale de la légalisation et réglementation du cannabis de Santé Canada pour fournir des renseignements sur l'usage du cannabis (marihuana) et des cannabinoïdes à des fins médicales. Le présent document est un résumé d'articles scientifiques examinés par les pairs et de revues internationales sur les utilisations thérapeutiques possibles et sur les effets néfastes du cannabis et des [...]
Lire la suite